eISSN: 1643-3750


Get your full text copy in PDF

NOC/oFQ activates PKC and generates superoxide to impair hypotensive cerebrovasodilation after hypoxia/ischemia.

William Armstead

Med Sci Monit 2002; 8(1): BR

ID: 420978

BACKGROUND: Previous studies have observed that hypotensive pial arterydilation was blunted following global cerebral ischemia in the piglet. In unrelated studies, superoxide(O-2) contributed to impaired hypotensive cerebrovasodilation following traumatic brain injury in therat while the opioid nociceptin/orphanin FQ (NOC/oFQ) generated O-2 via activation of protein kinaseC in the piglet. This study determined the contribution of NOC/oFQ, PKC activation and O-2 generationin hypoxic ischemic hypotensive cerebrovasodilation impairment.Material/Methods: Anesthetized newbornpigs equipped with a closed cranial window were used. Global cerebral ischemia was produced via elevatedintracranial pressure. Hypoxia, via inhalation of nitrogen, decreased PO2 to 34I3 mmHg. RESULTS: TopicalNOC/oFQ (10-10M), the CSF concentration following hypoxia/ischemia, had no effect on pial artery diameterby itself but attenuated hypotension (mean arterial blood pressure decrease of 44I2%) induced pial arterydilation (33I1 vs 19I2%). Coadministration of the PKC inhibitor chelerythrine (10-7M) or the O-2 scavengerpolyethylene glycol superoxide dismutase and catalase (SODCAT) with NOC/oFQ (10-10M) partially preventedhypotensive pial dilation impairment (34I2 vs 28I1% for SODCAT). Hypotensive pial artery dilation wasblunted by hypoxia/ischemia but such dilation was partially protected by the NOC/oFQ receptor antagonist[F/G] NOC/oFQ (1-13) NH2 (10-6M), chelerythine or SODCAT (34I1 vs 7I2 vs 21I2% for sham, H/I and H/I+ SODCAT, respectively). CONCLUSIONS: These data show that PKC activation and generation of O-2 contributesto hypoxia/ischemia impairment of hypotensive pial artery dilation. These data suggest that NOC/oFQ activatesPKC and generates O-2 to impair hypotensive cerebrovasodilation after hypoxia/ischemia.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree